Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Garassino, Marina Chiara; Reck, Martin; Chouaïd, C.; Bischoff, Helge; Reinmuth, Niels; Cove-Smith, Laura; Mansy, T.; Migliorino, Maria Rita; Delmonte, Angelo; Sánchez, José Garcia; Velarde, Luis Enrique Chara; Bernabé, R.; Paz‐Ares, Luis; Perez, I. Diaz; Trunova, Nataliya; Foroutanpour, Kayhan; Faivre-Finn, Corinne

doi:10.1016/j.jtho.2022.07.1148

Cited by 56 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Durvalumab treatment, which lasted for a median duration of 11 months, was also well tolerated in the real-world setting, with safety observations being aligned with the known profile of durvalumab administered after CRT in the unresectable, stage III NSCLC setting. 14,15,28 The outcomes from PACIFIC-R align with other realworld studies of the PACIFIC regimen. [29][30][31][32][33] For instance, Taugner et al 30 reported a rwPFS rate of 62% at 12 months with durvalumab in their prospective study, which is consistent with the corresponding rate from PACIFIC-R.…”

Section: Discussionsupporting

confidence: 63%

“…21 The favorable real-world outcomes found in the sCRT subset of PACIFIC-R complement recently published findings from the phase 2, single-arm, PA-CIFIC-6 trial, which revealed encouraging outcomes with durvalumab after sCRT. 28 Together, the findings of these studies suggest that durvalumab after sCRT could be a reasonable treatment strategy for patients who are considered unsuitable for cCRT; the benefit of this strategy is currently being investigated in the phase 3 PACIFIC-5 trial (NCT03706690).…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Girard¹,

Bar²,

Garrido³

et al. 2023

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 96%

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Girard¹,

Bar²,

Garrido³

et al. 2023

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

“…For patients with advanced NSCLC who could not tolerate concurrent chemoradiotherapy, sequential chemoradiotherapy was a standard treatment. In August 2022, the phase 2 PACFIC–6 trial reported durvalumab after sequential chemoradiotherapy achieved acceptable safety and encouraging efficacy ( 82 ). The phase 3 PACFIC–5 trial is ongoing to further evaluate the efficacy and safety of durvalumab after sequential or concurrent chemoradiotherapy for unresectable stage III NSCLC ( 82 ).…”

Section: Discussionmentioning

confidence: 99%

Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis

Liu

Han

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundImmunotherapy for lung cancer has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer immunotherapy.MethodOn 1 July, 2022, the authors identified 2,941 papers on lung cancer immunotherapy by the Web of Science and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top papers) as well as major journals on lung cancer immunotherapy. After that, recent research hotspots were analyzed based on the latest publications in major journals.ResultsThese 2,941 papers were cited a total of 122,467 times. “Nivolumab vs. docetaxel in advanced non–squamous non–small–cell lung cancer” published in 2015 by Borghaei H et al. was the most cited paper (5,854 citations). Among the journals, New England Journal of Medicine was most influential. Corresponding authors represented China took part in most articles (904) and papers with corresponding authors from the USA were most cited (139.46 citations per paper). Since 2015, anti–PD–(L)1 has become the hottest research area.ConclusionsThis bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on thousands of publications, and further suggests future research directions. Moreover, the results can benefit researchers to select journals and find potential collaborators. This study can help researchers get a comprehensive impression of the research landscape, historical development, and recent hotspots in lung cancer immunotherapy and provide inspiration for further research.

show abstract

“…Notably, the 3-year OS rates in PACIFIC and PACIFIC-R (NCT03798535) [90] and the sCRT and cCRT cohorts in the GEMSTONE-301 trial were 57.9%, 56.7%, 59.0%, and 54.1%, respectively (Table 6, Figure 3). Studies are currently testing differences in the combination patterns of ICI therapy and sCRT/cCRT according to differences in administration timing [91][92][93][94][95][96] (Figure 2). With respect to biomarkers, Moding et al [97] assessed the MRD status via ctDNA dynamic monitoring to explore its value in predicting the prognosis of patients with LA-NSCLC who received consolidation immunotherapy after chemoradiotherapy.…”

Section: Emerging Explorations On Top Of Pacific Modalitymentioning

confidence: 99%

Management of locally advanced non‐small cell lung cancer: State of the art and future directions

Miao,

Zhao,

Han

et al. 2023

Cancer Communications

View full text Add to dashboard Cite

Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one‐third of affected patients have locally advanced NSCLC (LA‐NSCLC, stage III NSCLC) at diagnosis. Because of its heterogeneity, LA‐NSCLC often requires multidisciplinary assessment. Moreover, the prognosis of affected patients is much below satisfaction, and the efficacy of traditional therapeutic strategies has reached a plateau. With the emergence of targeted therapies and immunotherapies, as well as the continuous development of novel radiotherapies, we have entered an era of novel treatment paradigm for LA‐NSCLC. Here, we reviewed the landscape of relevant therapeutic modalities, including adjuvant, neoadjuvant, and perioperative targeted and immune strategies in patients with resectable LA‐NSCLC with/without oncogenic alterations; as well as novel combinations of chemoradiation and immunotherapy/targeted therapy in unresectable LA‐NSCLC. We addressed the unresolved challenges that remain in the field, and examined future directions to optimize clinical management and increase the cure rate of LA‐NSCLC.

show abstract

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Cited by 56 publications

References 40 publications

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis

Management of locally advanced non‐small cell lung cancer: State of the art and future directions

Contact Info

Product

Resources

About